Tuesday Sep 20, 2022
To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 2
Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.
Guest speakers:
Mandy Leonard, PharmD, BCPS
Senior Director of Drug Use Policy and Formulary Management
Cleveland Clinic
Steven Lucio, PharmD, BCPS
Senior Principal in Pharmacy Solutions
Vizient
Moderator:
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
Show Notes:
[00:47 -3:06] Other factors driving aducanumab formulary decision making
[03:07-6:35] How CMS is managing this medication
[06:36-9:04] What should patients and families know about this medication?
[09:05-12:33] What frontline pharmacists should know about this medication
Links | Resources:
To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 1
American Academy of Neurology statement
Subscribe Today!